

Keywords: colorectal cancer; non-coding RNA; microRNA; prognosis

MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients

M Pichler^{*1,2}, A L Ress¹, E Winter³, V Stiegelbauer¹, M Karbiener⁴, D Schwarzenbacher¹, M Scheideler⁴, C Ivan², S W Jahn³, T Kiesslich^{5,6}, A Gerger¹, T Bauernhofer¹, G A Calin² and G Hoefler³

¹Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria; ²Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ³Institute of Pathology, Medical University of Graz (MUG), Graz, Austria; ⁴RNA Biology Group, Institute of Genomic and Bioinformatics, Graz University of Technology, Graz, Austria; ⁵Department of Internal Medicine I, Paracelsus Medical University/Salzbürger Landeskliniken (SALK), Salzburg, Austria and ⁶Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria

Background: MicroRNAs (miRNAs) regulate the biological properties of colorectal cancer (CRC) cells and might serve as potential prognostic factors and therapeutic targets. In this study, we therefore globally profiled miRNAs associated with E-cadherin expression in CRC cells in an attempt to identify miRNAs that are associated with aggressive clinical course in CRC patients.

Methods: Two CRC cell lines (Caco-2 and HRT-18) with different E-cadherin expression pattern were profiled for differences in abundance for more than 1000 human miRNAs using microarray technology. One of the most differentially expressed miRNAs, miR-200a was evaluated for its prognostic role in a cohort of 111 patients and independently validated in 217 patients of the Cancer Genome Atlas data set. To further characterise the biological role of miR-200a expression in CRC, *in vitro* miR-200a inhibition and overexpression were performed and the effects on cellular growth, apoptosis and epithelial–mesenchymal transition (EMT)-related gene expression were explored.

Results: *In situ* hybridisation specifically localised miR-200a in CRC cells. In both cohorts, a low miR-200a expression was associated with poor survival ($P < 0.05$). Multivariate Cox regression analysis identified low levels of miR-200a expression as an independent prognostic factor with respect to cancer-specific survival (HR = 2.04, CI = 1.28–3.25, $P < 0.002$). Gain and loss of function assays for miR-200a *in vitro* led to a significantly differential and converse expression of EMT-related genes ($P < 0.001$). A low expression of miR-200a was also observed in cancer stem cell-enriched spheroid growth conditions ($P < 0.05$).

Conclusions: In conclusion, our data suggest that low miR-200a expression is associated with poor prognosis in CRC patients. MiR-200a has a regulatory effect on EMT and is associated with cancer stem cell properties in CRC.

Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in males and ranks second in females, with 143 460 new cancer cases and 51 690 deaths estimated to occur in 2012 in the United States (Siegel *et al*, 2012). Despite the

introduction of novel treatment options, including anti-angiogenic agents and targeted agents against the epidermal growth factor receptor, metastatic CRC still remains an incurable disease in most cases (Chua *et al*, 2012). Given the high number of CRC-related

*Correspondence: Dr M Pichler; E-mail: martin.pichler@medunigraz.at

Revised 9 December 2013; accepted 9 January 2014; published online 6 February 2014

© 2014 Cancer Research UK. All rights reserved 0007–0920/14

deaths, the toxic side effects of current treatment modalities and their high costs, there remains a clear need for further deciphering the pathogenesis of CRC and establish novel prognostic and potential therapeutic factors (Heitzer *et al*, 2013a, b). In the last 10 years, the classical concept of tumour driving protein-coding genes was expanded by the identification of a novel class of small non-protein-coding RNA molecules known as microRNAs (miRNAs) (Calin and Croce, 2006). Due to their chemical stability, they provide great potential as novel diagnostic and prognostic biomarkers (Cortez *et al*, 2011; Pichler *et al*, 2012; Schwarzenbacher *et al*, 2013). Currently, several miRNAs have been established as differentially expressed and relevant for CRC pathogenesis including miR-150 (Ma *et al*, 2011), miR-28-5p/-3p (Almeida *et al*, 2012) and many others (Bartley *et al*, 2011). In general, miRNAs that regulate fundamental pathways and molecules involved in colorectal carcinogenesis should be considered as potential cancer driving factors. E-cadherin, a membranous adhesion molecule on epithelial cells, has been previously shown to be involved in proliferation, migration and the process of epithelial–mesenchymal transition (EMT) (Buda and Pignatelli, 2011). Loss of E-cadherin and cytoplasmic (versus membranous) expression promotes growth, invasion and drug resistance of CRC cells (Buda and Pignatelli, 2011; Chen *et al*, 2012). In this study, therefore, we profiled the differences in expression levels of more than 1000 miRNAs between two different CRC cell lines with significantly different expression patterns of the cell adhesion molecule E-cadherin. As one of the most differentially expressed miRNAs, miR-200a expression was further validated and located in CRC tissue by quantitative RT-PCR and *in situ* hybridisation. Based on the expression differences, we analysed whether alterations in miR-200a expression influence the prognosis of CRC patients. For characterisation of the biological effects of miR-200a in CRC cells, we performed *in vitro* transfection experiments to enhance or inhibit the function of miR-200a and studied the effects on proliferation, apoptosis, EMT-related gene expression and putative stem cell-enriched growth condition.

MATERIALS AND METHODS

CRC cell lines. The CRC cell lines Caco-2 and HRT-18 were purchased from American Type Culture Collection (Manassas, VA, USA). Caco-2 was grown in MEM with Earle's salts (minimum essential medium, PAA Laboratories, Pasching, Austria) supplemented with 2 mmol l⁻¹ of L-glutamine, 1.5 g l⁻¹ of sodium bicarbonate, 0.1 mmol l⁻¹ of nonessential amino acids, 50 units per ml of penicillin, 50 µg ml⁻¹ of streptomycin, and 10% FCS (PAA Laboratories). HRT-18 cells were maintained in RPMI 1640 (GIBCO Lifetech, Vienna, Austria) containing 2 mmol l⁻¹ of L-glutamine, 50 units per ml of penicillin, 50 µg ml⁻¹ of streptomycin and 10% FCS (v/v). After obtaining a confluence of ~80%, total RNA was isolated following a standard TRizol protocol and RNA was stored at -70 °C until further procedures. These two cell lines underwent an immunocytochemical staining of their E-cadherin expression and based on the difference, they were used for profiling the genome-wide expression of more than 1000 miRNAs. For transient transfection experiments, the easily transfectable human colorectal carcinoma cell line HCT116 was purchased from American Type Culture Collection. Cells were grown in McCoy's 5A modified Medium (w/o L-Glutamine, 2.2 g l⁻¹ sodium bicarbonate, from Biochrom, Berlin, Germany) containing 10% fetal bovine serum gold (PAA) and antibiotics (penicillin and streptomycin) and were incubated in a 5% CO₂ humidified incubator at 37 °C.

Immunocytochemistry. For characterisation of the expression levels and pattern (membranous or cytoplasmic) of E-cadherin cells from both CRC cell lines (Caco-2 and HRT-18), cells were

harvested, formalin fixed and paraffin embedded. Histological sections were deparaffinised in xylene and rehydrated with graded ethanol. For E-cadherin detection, sections were subjected to antigen retrieval for 40 min at room temperature in 0.01 M sodium citrate buffer, pH 6.0 and subsequently incubated for 60 min with a monoclonal E-cadherin antibody (VENTANA no.790-4497, Vienna, Austria). The reaction was visualised using the i-view DAB IHC detection Kit (VENTANA), and all sections were counterstained with hematoxylin. The frequency of positive cancer cells and the cellular localisation was assessed by two experienced pathologists (SWJ and GH).

MicroRNA microarray analysis. Microarrays were generated by spotting Nexterion HiSens E Sildes (Schott, ordered by Peqlab, Prod. no. 39-1125813, Erlangen, Germany) with the miRCURY LNA microRNA array ready-to-spot probe set, 6th gen, human, mouse & rat (Exiqon, prod. no. 208410, Vedbaek, Denmark). This probe set consists of 2383 unique capture probes, covering all mature miRNAs from human, mouse and rat annotated in miRBase version 16.0. For two-colour hybridisations, 1 µg total RNA of each sample was used for Hy3 and Hy5 labelling using the miRCURY LNA microRNA Hi-Power Labeling Kit (Exiqon, Prod. no. 208035) according to the manufacturer's instructions. Hybridisations were performed on a TECAN HS400 Hybridisation Station (Tecan, Männedorf, Switzerland). All hybridisations were repeated with reversed dye assignment (dye-swap). Hybridised slides were scanned with a GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA) at 10 µm resolution and the resultant TIFF images were analysed with GenePix Pro 4.1 software. Raw data were subsequently processed using ArrayNorm (Pieler *et al*, 2004) for normalisation and Genesis software for evaluation (Sturn *et al*, 2002). All experimental parameters, raw and processed data files were submitted to the public repository Gene Expression Omnibus (GEO accession GSE53095).

In situ hybridisation. To localise and confirm miR-200a expression in CRC tissue, an *in situ* hybridisation was performed according to the instruction manual of the miRCURY LNA microRNA ISH Optimization Kit (Exiqon) on formalin-fixed paraffin embedded (FFPE) CRC samples. The double-(5' and 3')-DIG labelled miRCURY LNA miRNA detection probes for human miR-200a, scrambled RNA as a negative control, and the 5'-DIG labelled U6 snRNA detection probe, seen as overall nuclear staining, were purchased from Exiqon. The probe has high affinity and discrimination, enabling specific and sensitive cellular detection of miR-200a.

Study population – cohort 1. Our retrospective study included data from 111 histologically confirmed CRC patients who underwent treatment at the Division of Oncology, Medical University of Graz between January 2002 and January 2012. The ethics committees of the Medical University of Graz approved this study (No. 23-545 ex 10/11). Patients' clinicopathological data were retrieved from medical records at the same institution. All cases were reviewed based on pathology reports and histological slides for pTNM categories and histopathological tumour grade. The medical records were particularly searched for the presence or absence of distant metastases (M stage), the UICC tumour stage (I–IV) and the number and characteristics of treatment lines. Patients were treated by standard surgery procedure and received adjuvant treatment when appropriate (stage II with risk factors or stage III). If advanced disease at the date of diagnosis was diagnosed, patients received medical treatment according to the current European ESMO guidelines (Van Cutsem *et al*, 2010). Post-treatment surveillance included routine clinical and laboratory examination. Regarding imaging methods, computer tomography was predominantly used. Dates of death were obtained from the central registry of the Austrian Bureau of Statistics or by telephone calls to their relatives.

Data set of the Cancer Genome Atlas – cohort 2. We downloaded and analysed data publicly available from the Cancer Genome Atlas Project (TCGA; <https://tcga-data.nci.nih.gov/tcga/>) for colon cancer patients. Level 3 Illumina miRNASeq (Illumina Sequencing Technology, San Diego, CA, USA; HiSeq, and Genome Analyzer) were used for miRNA expression. We derived from the ‘isoform_quantification’ files the ‘reads_per_million_miRNA_-mapped’ values for mature forms for each miRNAs. Statistical analyses were performed in R (version 2.15.0) (<http://www.r-project.org/>) and the statistical significance was defined as a *P*-value less 0.05. For survival analysis, the patients were grouped into percentiles according to miR-200a (MIMAT0000682 expression). The log-rank test was employed to determine the association between miRNA expression and survival and the Kaplan–Meyer method was used to generate survival curves. Cut off points to significantly split (log-rank test *P*-value <0.05) the samples into low/high miR-200a groups were recorded. The cut off to optimally separate the patients was chosen.

Measurement of miR-200a expression level by qRT–PCR. RNA was extracted from both tumour tissue and adjacent non-neoplastic colon mucosa. Two to eight 10 μ m-thick tissue sections were used for microdissection to obtain areas with at least 60% tumour cells. miRNAs were isolated using the miRNeasy FFPE Kit 50 (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. cDNA was synthesised from 500 ng of total RNA using a miScript Reverse Transcription Kit (Qiagen). Quantification of miRNAs was performed using the miScript SYBR Green PCR kit (Qiagen) and the Hs_miR-200a miScript Primer Assay (Qiagen) according to the manufacturer’s recommendations on a LightCycler 480 real-time PCR device (Roche, Mannheim, Germany). qRT–PCR was carried out using normalisation to RNU6B as was recently published (Ma *et al*, 2011; Almeida *et al*, 2012). Differences in fold expression with regard to the adjacent normal colon mucosa were calculated from triplicates C_t values following the $2^{-\Delta\Delta C}$ method (Schmittgen and Livak, 2008).

For detection of miR-200a from cell lines after transfection experiments, 1 μ g of total RNA was reverse transcribed by the miScript II RT Kit (Qiagen) according to the manufacturer’s protocol. The Hs_miR-200a_1 miScript Primer Assay (mature miRNA sequence: 5’-U AACACUGUCUGGUAACGAUGU-3’, Qiagen) and for normalisation the Hs_RNU6-2_1 miScript Primer Assay (Qiagen) were applied on a LightCycler 480 Real-Time PCR System (Roche Diagnostics) using miScript SYBR Green PCR Kit (Qiagen).

In vitro transfection experiments of miR-200a mimetics/inhibitors. For a transient transfection approach with the aim to inhibit or enhance the miR-200a function, HCT116 cells were transfected using the fast forward transfection protocol as suggested by the HiPerFect Transfection Reagent (Qiagen) protocol according to the manufacturer’s instructions. A specific miR-200a inhibitor (Anti-Hsa-MiR-200a-3p, inhibitor for the sequence: 5’-U AACACUGUCUGGUAACGAUGU-3’, Qiagen) and mimetic (Syn-Hsa-mir-200a-3p, mimetics for the sequence: 5’-U AACACUGUCUGGUAACGAUGU-3’, Qiagen) were commercially purchased. For the reference to normalise the findings, we used the miScript inhibitor negative Control (Qiagen) under the same concentrations and conditions as used for the inhibitor/mimetic (10–50 nM). For confirmation of transfections efficacy, the AllStars cell death control (Qiagen) was used. For measuring gene expression changes after miR-200a inhibition/overexpression, we seeded 2×10^5 HCT116 cells in complete medium in 6-well plates. miRNA inhibitor/mimetic–transfection complexes were added according to the fast forward transfection protocol as recommended by the manufacturer (HiPerFect Transfection Reagent, Qiagen). Transfected cells were incubated under their normal growth conditions (37 °C, 5% CO₂) and the effect of miR-200a manipulations on changes in gene expression levels were measured

by quantitative RT–PCR after 48 h as described above. Experiments with the concentrations described above and the following gene expression measurement were repeated eight independent times. Gene expression was evaluated with regard to proliferation-related genes (cyclin D1 and p27-CDKN1B) and EMT-related genes (E-cadherin and vimentin). For mRNA quantification, up to 1 μ g of total RNA was reverse transcribed into cDNA using the miScript II RT Kit (Qiagen) according to the manufacturer’s instructions. Quantitative RT–PCR was carried out in triplicates for each sample using commercially available primers specific for the proliferation markers cyclin D1 (Hs_CCND1_1_SG QuantiTect Primer Assay, Qiagen) and CDKN1B (Hs_CDKN1B_2_SG QuantiTect Primer Assay), EMT-related genes (E-cadherin, Hs_CDH1_1_SG QuantiTect primer assay, Qiagen; Vimentin, Hs_VIM_1_SG QuantiTect primer assay, Qiagen) and the housekeeping gene GAPDH (Hs_GAPDH_1_SG QuantiTect Primer Assay, Qiagen) on a LightCycler 480 Real-Time PCR System (Roche Diagnostics) using QuantiTect SYBR Green PCR Kit (Qiagen). GAPDH was used for normalisation and relative gene expression levels were calculated according to $2^{-\Delta\Delta C}$ method (Schmittgen and Livak, 2008).

Profiling EMT-related genes on a RT² profiler PCR array. We used the Epithelial to Mesenchymal Transition RT² Profiler PCR Arrays (Qiagen) to screen the mRNA expression of multiple genes related to EMT in HCT116 cells, which were transfected with the specific miR-200a inhibitor and mimetic in comparison with the respective control (miScript negative Control, Qiagen). RNA was isolated using the RNeasy Mini Kit (Qiagen) and 500 ng of total RNA was reverse transcribed into cDNA using the RT² First Strand Kit (Qiagen) according to the manufacturer’s instructions. Quantitative RT–PCR was carried out in triplicates for each sample on a LightCycler 480 Real-Time PCR System (Roche Diagnostics) using RT² Real-Time SYBR Green qPCR Master Mix (SABiosciences, Qiagen). All analyses were performed using the web-based PCR Array Data Analysis Software tool provided on the SABiosciences website. Geometric mean of the housekeeping genes ACTB, GAPDH and RPLP0 was used for normalisation and fold change was used to analyse differences in gene expression.

WST-1 proliferation assay. To test whether miR-200a expression influences cellular growth rates of CRC cells, we performed modulation experiments with the miR-200a mimetic and inhibitor and measured the cellular growth rate by applying the WST-1 proliferation assay. In more detail, after standard trypsinisation 2×10^4 HCT116 cells per well were seeded in a 96-well culture plate. After transfection with a miR-200a mimetic, cells were incubated in regular McCoy’s 5A modified Medium growth medium (Biochrom) for 48 h and the WST-1 proliferation reagent (Roche Applied Science) was applied according to the manufacturer’s recommendations. After 4 h, colorimetric changes were measured using a SpectraMax Plus (Molecular Devices) at a wavelength of 450 nm with a reference wavelength at 620 nm.

Apoptosis assay. To clarify the role of miR-200a in apoptosis, we carried out a commercially available apoptosis assay after modulation of miR-200a. In more detail, 2×10^4 HCT116 cells were seeded in each well of a 96-well plate and were transiently transfected with Syn-Hsa-mir-200a (Qiagen) and Anti-Hsa-mir-200a (Qiagen). Caspase activity was measured after 24 and 48 h in HCT116 cells using the Caspase-Glo 3/7 Assay Systems (Promega, Madison, WI, USA) according to manufacturer’s instructions. Luminescence was measured in a POLARstar OPTIMA microplate reader (BMG Labtech, Ortenberg, Germany).

Tumour sphere formation. To measure differences in normal adherent HCT116 cells and tumour spheres, which are considered to be enriched of stem/progenitor cancer cells, we established a spheroid growth model as previously described (Fang *et al*, 2010). In detail, the adherent growing HCT116 cell line was dissociated

into single cells using trypsin/EDTA and seeded in ultra-low attachment flasks (Corning) using in serum-free McCoy5A medium. Serum-free McCoy5A medium was supplemented with $1 \times$ B27 supplement (GIBCO), 20 ng ml^{-1} human epidermal growth factor (Peprotech, Rocky Hill, NJ, USA), 20 ng ml^{-1} human basic fibroblast growth factor (Peprotech), 20 IU ml^{-1} Heparin (Baxter, Vienna, Austria), 4 IU l^{-1} insulin Actrapid (Novo Nordisk, Vienna, Austria) and 1% antibiotic/antimycotic solution (Sigma-Aldrich, Vienna, Austria). Self-renewing capacity of HCT116 spheres was shown by dissociating the spheres into single cells that were reseeded to yield the next generation of colon spheres. Spheres were maintained for several passages. Splitting and dissociation of colon spheres were done using TrypLE Select (GIBCO). RNA was extracted by miRNeasy Kit (Qiagen) and miR-200a levels were compared between adherent and spheroid growing cells.

Statistical analyses. All statistical analyses were performed using SPSS version 19.0 software (SPSS, Chicago, IL, USA). As reported previously, the continuous variable miR-200a was analysed as dichotomous variable according to approximate cut off point (Atzpodien *et al*, 2003). The value that best discriminated between good and poor survival, that is with the most significant *P*-value according to the log-rank test, was determined by testing all possible cut offs. This cut off was then rounded to clinically convenient value. For miR-200a expression, this means that a cut off near the normal expression level (i.e. neoplastic miR-200a expression level is approximately equal to normal colon mucosa) was identified as

the optimal cut off, and therefore we defined low miRNA-200a expression as a lower expression level than that of adjacent non-cancerous tissue ($n = 60$), whereas high miR-200a expression was defined as expression levels being higher than in adjacent non-tumour tissue ($n = 51$). Fisher's exact test, χ^2 test and Mann-Whitney were used to analyse the association between miR-200a expression and clinicopathological parameters. Cancer-specific survival (CSS) was defined as the time from date of diagnosis to the date of cancer-related death. Cancer-specific survival was assessed using the Kaplan-Meier method, and the log-rank test was performed to compare the survival curves of individual groups. Univariate and multivariate Cox proportional hazard models including age, gender, tumour stage (according to the AJCC/UICC 2010 TNM classification), tumour grade, number of therapies and miR-200a expression were used to determine the clinicopathological parameters that were statistically significant for CSS. The reported results included hazard ratios (HR) and 95% confidence intervals (CI). All experiments were at least repeated for three independent times.

RESULTS

To identify miRNAs that determine the course of aggressive biological behaviour of CRC, we globally profiled the miRNA expression levels of two different CRC cell lines according to their E-cadherin expression pattern. The Caco-2 CRC cells exhibited a lower E-cadherin expression level with pronounced cytoplasmic




Figure 1. Microarray-based miRNA expression profiling in the CRC cell lines Caco-2 versus HRT-18 revealed 19 miRNAs as significantly differentially expressed after Benjamini-Hochberg correction for multiple testing (red line) including miR-200a (red arrow). Red colour code represents an upregulation in HRT-18 cells, green colour code represents a downregulation compared with Caco-2 cells. The full colour version of this figure is available at *British Journal of Cancer* online.

staining pattern, in comparison with the HRT-18 CRC cell line, which showed a strong membranous E-Cadherin staining (Supplementary Figure 1). For detection of miRNA expression differences between both cell lines, we used a comprehensive miRNA detection system that detects more than 1000 human miRNAs. The rationale for using cell lines instead of CRC tissue was to avoid contamination of miRNAs from tumour microenvironment. A comparison of miRNA expression levels between the two different cell lines is shown in Figure 1. Overall, we identified 32 small RNAs including small nucleolar RNAs as significantly differentially expressed ($P < 0.05$), and 19 of these RNAs remained significant after performing a Benjamini–Hochberg correction for multiple testing. The differentially expressed miRNAs included miR-200a that has been previously involved in the pathogenesis of many different human cancer types (Gregory *et al*, 2008). This prompted us to focus our further analysis on miR-200a and at first, we confirmed the array-based findings by qRT-PCR comparing the two cell lines ($P < 0.05$, data not shown). To substantiate our findings from cell lines and to explore whether miR-200a deregulation might serve as a tissue-based biomarker that is not confounded by surrounding non-epithelial cells, we attempt to visualise and localise miR-200a expression within the CRC tissue by ISH. As demonstrated by ISH, miR-200a predominantly localises in CRC cells, whereas the surrounding non-epithelial cells showed only weak or no staining (Figure 2). The difference in

expression in different cell lines and the specific localisation in CRC tissue, prompted us to test whether miR-200a expression might serve as a prognostic biomarker for CRC patients. Thus, we measured miR-200a expression on a collection of 111 CRC patients. Clinicopathological characteristics of the study cohort are summarised in Supplementary Table 1. Median follow-up was 38 months (interquartile range: 24–64). The median expression level of miR-200a was 0.88-fold (ranging from 0.11–10.3, Supplementary Table 2) lower in neoplastic tissue compared with adjacent non-neoplastic colon mucosa. For evaluating whether the levels of miR-200a expression influence survival of CRC patients, we divided the cohort into two groups according to a calculated cut off value, which was optimised as described above in the Material and Methods section (Atzpodien *et al*, 2003). The level of miR-200a expression was categorised into low ($n = 60$) and high ($n = 51$), respectively, compared with the expression in the corresponding non-neoplastic colon tissue. Subsequently, we used this cut off for clinicopathological parameters and survival analysis. Low miR-200a expression was not significantly associated with gender, tumour location, T stage, presence of metastasis at diagnosis, tumour grade and clinical stage (all P -values > 0.05 , Supplementary Table 3). Univariate analysis identified colonic location (colon versus rectum), high tumour grade (G3 versus G1 + G2), advanced tumour stage (stage IV versus stage II–III), no metastasectomy and low expression of miR-200a as poor prognosticators for CSS (all P -values < 0.05),




Figure 2. *In situ* hybridisation to specifically localise the expression of miR-200a in CRC tissue. (A) Hematoxylin-eosin stained cancer tissue (CRC) and adjacent non-neoplastic tissue (N). (B) Positive control RNU6B localises all epithelial and non-epithelial cells (blue staining). (C and E) The specific probe localizes miR-200a mainly to invasive CRC formations. (D and F) Corresponding tissue probed with negative control for scrambled RNA is shown. Arrow denotes gland shown in high power view of inset (C and D). The full colour version of this figure is available at *British Journal of Cancer* online.

whereas age, gender and number of therapy lines were not significantly associated with CSS (Table 1). The median survival for patients with high miR-200a expression was 61 months, whereas the median survival for patients with low miR-200a expression was 33 months ($P < 0.001$). Figure 3 shows the Kaplan–Meier curve for CSS and reveals that low miR-200a expression is a significant factor for poor prognosis in CRC ($P < 0.001$, log-rank test). To test whether the prognostic value of low miR-200a expression was independent of other risk factors for poor survival, a multivariate analysis was performed using a Cox proportional hazard model. Multivariate analyses including age, gender, tumour location, tumour grade, tumour stage, miR-200a expression, lines of therapy and metastasectomy demonstrated that low miR-200a expression was an independent predictor for poor CSS in CRC patients (HR = 2.04, CI = 1.28–3.25, $P = 0.002$). Statistically significant results were also obtained for high tumour grade ($P = 0.02$), advanced tumour stage ($P < 0.001$), whereas all other parameters were not significant for CSS (Table 2).

For further validation of the prognostic significance of miR-200a expression in an independent data set, we also analysed RNA seq data from the TCGA data set. In 217 colon cancer patients, we confirmed that a low expression of miR-200a is associated with poor survival ($P = 0.0166$, Figure 4).

Table 1. Univariate analysis of clinicopathological parameters for the prediction of cancer-specific survival in patients with colorectal cancer ($n = 111$)

Parameter	Cancer-specific survival	
	HR (95% CI)	P-value
Age at diagnosis (years)		
≤ 60	1 (reference)	0.658
> 60	1.10 (0.71–1.69)	
Gender		
Male	1 (reference)	0.398
Female	0.82 (0.52–1.29)	
Tumour location		
Colon	1 (reference)	0.024
Rectum	0.84 (0.73–0.97)	
Tumour grade		
G1 + G2	1 (reference)	0.002
G3	2.11 (1.32–3.38)	
Tumour stage		
II + III	1 (reference)	< 0.001
IV	2.64 (1.68–4.14)	
Lines of therapy		
≤ 3	1 (reference)	0.190
> 3	0.75 (0.49–1.15)	
Metastasectomy		
No	1 (reference)	0.032
Yes	0.58 (0.35–0.95)	
MiR-200a expression		
High	1 (reference)	0.001
Low	2.13 (1.38–3.30)	

Abbreviations: CI = confidence interval; HR = hazard ratio.

In an attempt to identify possible tumour characteristics and mechanisms that might be associated with worse clinical outcome in CRC patients with low miR-200a expression, we conducted *in vitro* overexpression/inhibition experiments with miR-200a mimetic/inhibitor. After transfection of miR-200a mimetic/inhibitor, we measured a dose-dependent increase of 500–4000-fold overexpression with the mimetic and a decrease of miR-200a expression between 30–50% by using the inhibitor, respectively (data not shown). First, we explored the role of miR-200a in EMT-related gene expression. Using a PCR array that contains a dozen of EMT-related genes, we screened whether the enhanced expression of miR-200a induces changes in gene expression of this gene set. Several genes including the well-known EMT-related E-cadherin (upregulation), vimentin or ZEB1 (downregulation) were differentially expressed (Supplementary Figure 2). We confirmed these findings by a RT-PCR assay for E-cadherin and vimentin, two well-known EMT-marker genes, which demonstrated converse effects on E-cadherin (miR-200a overexpression: 1.48 ± 0.23 -fold change versus miR-200a inhibition 0.87 ± 0.09 -fold change, $P < 0.001$) and vimentin (miR-200a overexpression: 0.57 ± 0.1 -fold change versus miR-200a inhibition 1.1 ± 0.05 -fold change, $P < 0.001$, Supplementary Figure 3). Regarding cell growth, proliferation-related gene expression or apoptotic activity, we could not observe any differences in miR-200a overexpressing HCT116 cells compared with miR-200a-inhibited cells (data not shown). Finally, we compared the expression of miR-200a in adherent versus spheroid growing HCT116 CRC cells, and detected a significant lower expression in the spheroid cancer stem cell model (0.48 ± 0.07 -fold change in spheroid cells versus adherent growing, $P < 0.05$, Supplementary Figure 4).

DISCUSSION

Novel biomarkers that are able to predict the clinical outcome of CRC patients will provide a valuable tool for risk stratification and patient surveillance and ideally provide a basis for decision making




Figure 3. Kaplan–Meier plot for CSS in CRC patients ($n = 111$) dichotomized by miR-200a expression level. In brackets are the numbers of patients in each group.

Table 2. Multivariate analysis of clinicopathological parameters for the prognosis of cancer-specific survival in patients with colorectal cancer (n = 111)

Parameter	Cancer-specific survival	
	HR (95% CI)	P-value
Age at diagnosis (years)		
≤60	1 (reference)	0.811
>60	0.94 (0.59–1.51)	
Gender		
Male	1 (reference)	0.816
Female	0.94 (0.58–1.58)	
Location		
Colon	1 (reference)	0.064
Rectum	0.62 (0.38–1.02)	
Tumour grade		
G1 + G2	1 (reference)	0.020
G3	1.80 (1.09–2.96)	
Tumour stage		
II + III	1 (reference)	<0.001
IV	3.12 (1.89–5.16)	
MiR-200a expression		
High	1 (reference)	0.002
Low	2.04 (1.28–3.25)	
Lines of therapy		
<3	1 (reference)	0.556
≥3	0.87 (0.54–1.38)	
Metastastectomy		
No	1 (reference)	0.078
Yes	0.60 (0.34–1.05)	

Abbreviations: CI = confidence interval; HR = hazard ratio.

to avoid a potentially harmful, expensive and ineffective therapy. Different strategies have been performed to identify differentially expressed miRNAs in CRC, which often provided a comparison of normal versus cancerous tissue. However, contamination by cells of the tumour microenvironment, different regions of the cancerous tissue (tumour center or invasion front) and different sampling strategies (including different times of hypoxia and stress response) can impact miRNA levels in previously reported profiling studies (Iorio and Croce, 2012). Therefore, we first profiled miRNA expression based on differences in E-cadherin expression pattern in two different CRC cell lines for differences for more than 1000 miRNAs and identified several miRNAs as differentially expressed. One of these, miR-200a has been previously shown to be involved in regulation of E-cadherin expression as well as having a role in the pathogenesis of several types of cancer (Saydam *et al*, 2009). Therefore, we focused on miR-200a. Using *in situ* hybridisation, we confirmed specific expression in CRC cells, which provided the basis for further evaluation of the clinical value of miR-200a in a cohort of CRC patients. We identified low miR-200a expression as an independent prognostic parameter for CSS in CRC patients and independently confirmed our findings in a data set of an independent cohort.




Figure 4. Analysis of miR-200a for samples of colon cancer patients analysed on HiSeq platform from The Cancer Genome data set. MiR-200a low expression is significantly associated poor survival. In brackets are the numbers of patients in each group.

Encouraged by previously reported data about the role of miR-200 family as a regulator of EMT, we demonstrated by using two different assays an important role of miR-200a in EMT-related gene expression levels. In addition to EMT-related gene expression, we could also observe lower levels of miR-200a in spheroid growing cancer cells, a cell culture model that is assumed to contain more cancer stem cells (Fang *et al*, 2010). Thus, the shorter survival within the group of CRC patients with miR-200a low expression might be explained in part by differences in the EMT and stem cell formation capacity of their tumours. In line with our data, is the role of miR-200a that has been reported for the first time by Gregory *et al* (2008) who demonstrated that miR-200a was markedly downregulated in breast cancer cells that had undergone EMT, a process that is strongly associated with cancer cell invasion and metastases. On the molecular level, miR-200a suppresses the expression of the E-cadherin transcriptional repressors ZEB1 and ZEB2, transcription factors that induce the transition from an epithelial phenotype to a mesenchymal phenotype (Gregory *et al*, 2008). The transcriptional activity of miR-200a promoter region is repressed when ZEB1 and ZEB2 are upregulated through a conserved pair of ZEB-type E-box elements located proximal to the transcription start site (Bracken *et al*, 2008). Another self-reinforcing regulatory loop represents the interaction of miR-200a and SLUG, a protein that is not only a target of miR-200a but also directly represses miR-200a transcription in prostate adenocarcinoma (Liu *et al*, 2012). Recently, one study reported about the association of SIX1 and EMT in CRC. This study showed that SIX1 promotes EMT by repression of miR-200a in CRC cells (Ono *et al*, 2012). Wellner *et al* (2009) also linked the ZEB1 expression and members of the miR-200 family to tumour-initiating stem cells. Davalos *et al* (2012) demonstrated that miR-200a expression is commonly regulated by DNA methylation in human cancer. Recently, a study by Paterson (2013) showed that members of the miR-200 family are downregulated in the initial stages of stromal invasion. Besides the biological functions of members of the miR-200 family, they carry also great potential as non-invasive prognostic biomarkers. A very recently published study indicates that high miR-200c serum levels might represent a novel non-invasive prognostic marker in CRC patients (Toiyama *et al*, 2013).

In conclusion, this study indicates that high miR-200a expression is associated with membranous E-cadherin expression in CRC and a loss of miR-200a expression identifies patients with poor survival. MiR-200a regulates EMT-related gene expression and seems to be differentially expressed in CRC stem cells, which indicates this miRNA as a potential drug target in CRC.

ACKNOWLEDGEMENTS

Martin Pichler was supported by the funding of the START Funding programme of the Medical University of Graz, Austria, the Styrian government, by an Erwin Schroedinger Scholarship of the Austrian Science Funds (No. J3389-B23) (all to MP) and by Oesterreichische Nationalbank (Anniversary Fund, project number: 14869). Armin Gerger is supported by research grants from the Oesterreichische Nationalbank (Anniversary Fund, project number: 15400) and the Austrian Science Fund (FWF): (KLI 191).

REFERENCES

- Almeida MI, Nicoloso MS, Zeng L, Ivan C, Spizzo R, Gafa R, Xiao L, Zhang X, Vannini I, Fanini F, Fabbri M, Lanza G, Reis RM, Zweidler-McKay PA, Calin GA (2012) Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. *Gastroenterology* **142**(4): 886–896e9.
- Atzpodien J, Royston P, Wandert T, Reitz M (2003) Metastatic renal carcinoma comprehensive prognostic system. *Br J Cancer* **88**(3): 348–353.
- Bartley AN, Yao H, Barkoh BA, Ivan C, Mishra BM, Rashid A, Calin GA, Luthra R, Hamilton SR (2011) Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. *Clin Cancer Res* **17**(23): 7283–7293.
- Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, Goodall GJ (2008) A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. *Cancer Res* **68**(19): 7846–7854.
- Buda A, Pignatelli M (2011) E-cadherin and the cytoskeletal network in colorectal cancer development and metastasis. *Cell Commun Adhes* **18**(6): 133–143.
- Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. *Nat Rev Cancer* **6**(11): 857–866.
- Chen X, Wang Y, Xia H, Wang Q, Jiang X, Lin Z, Ma Y, Yang Y, Hu M (2012) Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis. *Mol Biol Rep* **39**(6): 6707–6714.
- Chua TC, Liauw W, Chu F, Morris DL (2012) Viewing metastatic colorectal cancer as a curable chronic disease. *Am J Clin Oncol* **35**(1): 77–80.
- Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA (2011) MicroRNAs in body fluids—the mix of hormones and biomarkers. *Nat Rev Clin Oncol* **8**(8): 467–477.
- Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, Esteller M (2012) Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. *Oncogene* **31**(16): 2062–2074.
- Fang DD, Kim YJ, Lee CN, Aggarwal S, McKinnon K, Mesmer D, Norton J, Birse CE, He T, Ruben SM, Moore PA (2010) Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. *Br J Cancer* **102**(8): 1265–1275.
- Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nat Cell Biol* **10**(5): 593–601.
- Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Hofler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR (2013a) Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. *Cancer Res* **73**(10): 2965–2975.
- Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Hofler G, Eisner F, Petru E, Sill H, Samonigg H, Pantel K, Riethdorf S, Bauernhofer T, Geigl JB, Speicher MR (2013b) Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. *Int J Cancer* **133**(2): 346–356.
- Iorio MV, Croce CM (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. *EMBO Mol Med* **4**(3): 143–159.
- Liu YN, Yin JJ, Abou-Kheir W, Hynes PG, Casey OM, Fang L, Yi M, Stephens RM, Seng V, Sheppard-Tillman H, Martin P, Kelly K (2012) MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms. *Oncogene* **32**(3): 296–306.
- Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W, Qin H (2011) miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. *Gut* **61**(10): 1447–1453.
- Ono H, Imoto I, Kozaki K, Tsuda H, Matsui T, Kurasawa Y, Muramatsu T, Sugihara K, Inazawa J (2012) SIX1 promotes epithelial-mesenchymal transition in colorectal cancer through ZEB1 activation. *Oncogene* **31**(47): 4923–4934.
- Paterson EL, Kazenwadel J, Bert AG, Khew-Goodall Y, Ruszkiewicz A, Goodall GJ (2013) Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. *Neoplasia* **15**(2): 180–191.
- Pichler M, Winter E, Stotz M, Eberhard K, Samonigg H, Lax S, Hoefler G (2012) Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. *Br J Cancer* **106**(11): 1826–1832.
- Pieler R, Sanchez-Cabo F, Hackl H, Thallinger GG, Trajanoski Z (2004) ArrayNorm: comprehensive normalization and analysis of microarray data. *Bioinformatics* **20**(12): 1971–1973.
- Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, James MF, Tannous BA, Stemmer-Rachamimov AO, Yi M, Stephens RM, Fraefel C, Gusella JF, Krichevsky AM, Breakefield XO (2009) Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. *Mol Cell Biol* **29**(21): 5923–5940.
- Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* **3**(6): 1101–1108.
- Schwarzenbacher D, Balic M, Pichler M (2013) The role of microRNAs in breast cancer stem cells. *Int J Mol Sci* **14**(7): 14712–14723.
- Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. *CA Cancer J Clin* **62**(1): 10–29.
- Sturn A, Quackenbush J, Trajanoski Z (2002) Genesis: cluster analysis of microarray data. *Bioinformatics* **18**(1): 207–208.
- Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A (2013) Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. *Ann Surg*; e-pub ahead of print 26 August 2013; doi:10.1097/SLA.0b013e3182a6909d.
- Van Cutsem E, Nordlinger B, Cervantes A (2010) Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. *Ann Oncol* **21**(Suppl 5): v93–v97.
- Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schuler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. *Nat Cell Biol* **11**(12): 1487–1495.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)